Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Proof of Principle Program - Phase I

University of Toronto

$155,600.00

Development and therapeutic validation of GPR55 modulators for the treatment of osteoclast-mediated disorders

EF 2015-16

Résumé
GPR55 is a biological target which has been shown to play an important role in a number of important aspects of human biology and human disease. Perhaps of greatest significance, it is found in highest concentrations in the most aggressive forms of breast cancer. We have shown that blocking GPR55 prevents tumour cell proliferation, invasion and migration. In recent studies we have also shown that blocking GPR55 increases bone mass by reducing the activity of the cells which remove bone (osteoclasts). These cells play the major role in the development of many bone tumours: drugs which suppress osteoclast activity are widely used in the treatment of osteoporosis and bone cancer, reducing the risk of bone fractures, slowing the spread of the tumour and providing relief from bone pain. Thus, drugs which block GPR55 (antagonists) appear to have a unique potential for a threefold approach to the treatment of osteoclast-mediated diseases, including cancers which metastasise to bone. Although GPR55 has been known as a promising target for the treatment of human disease for over 15 years, little progress has been made due to the complexities of the pharmacology and lack of availability of effective assays to use for probing the target. Recently, we have been able to optimise an assay which allows us to study compounds for their real effects on GPR55 and have been able to generate data which reinforces the assertion of an action against osteoclasts. We have teamed up with the acknowledged world experts in the development of compounds which target GPR55 (the Sanford-Burnham Institute): this partnership will generate highly potent GPR55 antagonists suitable both for clinical development and for validating the therapeutic potential of targeting GPR55. Thus we expect this programme to develop drugs which, if successful in the clinic, will give enormous benefit to millions of cancer patients, both saving lives and improving quality of life for patients.
Programme
Proof of Principle Program - Phase I
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
335097
Name
Ross Ruth A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Development and therapeutic validation of GPR55 modulators for the treatment of osteoclast-mediated disorders
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$155,600
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Bone; Cancer; Cannabinoid; Drug Discovery
Abstract
GPR55 is a biological target which has been shown to play an important role in a number of important aspects of human biology and human disease. Perhaps of greatest significance, it is found in highest concentrations in the most aggressive forms of breast cancer. We have shown that blocking GPR55 prevents tumour cell proliferation, invasion and migration. In recent studies we have also shown that blocking GPR55 increases bone mass by reducing the activity of the cells which remove bone (osteoclasts). These cells play the major role in the development of many bone tumours: drugs which suppress osteoclast activity are widely used in the treatment of osteoporosis and bone cancer, reducing the risk of bone fractures, slowing the spread of the tumour and providing relief from bone pain. Thus, drugs which block GPR55 (antagonists) appear to have a unique potential for a threefold approach to the treatment of osteoclast-mediated diseases, including cancers which metastasise to bone. Although GPR55 has been known as a promising target for the treatment of human disease for over 15 years, little progress has been made due to the complexities of the pharmacology and lack of availability of effective assays to use for probing the target. Recently, we have been able to optimise an assay which allows us to study compounds for their real effects on GPR55 and have been able to generate data which reinforces the assertion of an action against osteoclasts. We have teamed up with the acknowledged world experts in the development of compounds which target GPR55 (the Sanford-Burnham Institute): this partnership will generate highly potent GPR55 antagonists suitable both for clinical development and for validating the therapeutic potential of targeting GPR55. Thus we expect this programme to develop drugs which, if successful in the clinic, will give enormous benefit to millions of cancer patients, both saving lives and improving quality of life for patients.
Competitiondate
201509
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ross, Ruth A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $155,600~ $0~